Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Romaniello D, Marrocco I, Belugali Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I, Oren R, Lindzen M, Ghosh S, Kreitman M, Kittel JC, Gaborit N, Bergado Baez G, Sanchez B, Eilam R, Pikarsky E, Paz-Ares L, Yarden Y.
Romaniello D, et al. Among authors: kreitman m.
Cancers (Basel). 2020 Aug 24;12(9):2394. doi: 10.3390/cancers12092394.
Cancers (Basel). 2020.
PMID: 32847130
Free PMC article.